A recent article was published about the new partnership of the company Tempus and the University of Chicago Medicine. This partnership is designed to work together to create a treatment for cancer that is individualized for each patient, and eventually to hopefully find a cure. Tempus uses new technologies, including machine learning and molecular sequencing to figure out which treatments will work best with each individual patient’s genetic makeup. These new technologies could be a huge gamechanger in the both the medical field, with doctors and patients better able to fight cancer, but also in the “cancer business.” Current cancer treatment is extremely expensive, and only a handful of companies rule the market. However, this new and very disruptive form of technology could turn the entire industry on its head. Eric Lefkofsky, founder of Tempus, is the master of disruptive technologies.
Eric Lefkofsky has devoted his life to creating companies focused on technology and getting it to consumers. He is the co-founder of several different technology manufacturing, logistics, investment, and research companies, and he has devoted his life to the theoretical and practical application of these technologies. Lefkofsky is also a professor of applied technology and disruptive business modeling at the University of Chicago, and has had jobs at both DePaul University and Northwestern University as well.
When he is not creating new tech, Eric Lefkofsky is helping his wife run the Lefkofsky Family Foundation. This private, charitable foundation focuses on helping organizations that have an impact on their communities around the Chicago are. To date, the Foundation has helped over 50 organizations with new projects and initiatives. Lefkofsky is also on the Board of Trustees for many different organizations, including the Children’s Hospital of Chicago and the Art Institute of Chicago. Through his work with new technology and his philanthropic tendencies, Eric Lefkofsky is truly trying to make the world a better place.
Oncotarget is a medical journal covering various areas of research such as biology and medicine. The journal’s publications are peer-reviewed and are open to the public. Impact Journals is the publisher of Oncotarget. It was started in 2010. The editors of the Oncotarget are Andrei Gurkov and Michael Blagosklonny. Both of them work at the Roswell Park Cancer Institute in New York. The editorial board includes someNobel Prize winners and Lasker Award winners.
The home page of its site contains news about the journal and a bio of the journal. The bio explains the types of fields that the journal publishes including immunology, endocrinology, neuropathology, cardiology, and gerotarget. Oncotarget’s mission is to make research widely and readily available. It also allows the sharing of scientific discoveries. The journal is published on a weekly basis to ensure that there is no backlog of the investigation papers. Oncotarget facilitates the collaboration of scientists from different fields and brings forth novel ways of solving problems.
There are links to other pages of the site including the archives, search page, authors’ page, publication ethics, and the contact information page. A visitor on the site can see the previous issues through the archives page, see all the authors affiliated with Oncotarget, and search for papers that they might be interested in finding. The homepage also shows the current issue of the journal that is out at that time. The archives are accessed by visiting the Archives link on the homepage.
Read more: MET amplification as a potential therapeutic target in gastric cancer
There are different ways to reach the Oncotarget team through the various social media platforms. These include Facebook, Twitter, LinkedIn, and Google Plus. They also have an active presence on YouTube where they release videos. Oncotarget has an Impact Factor of 5.008 for 2015/16. It has had an average of 5.415 over the past five years.
Oncotarget journal has published some breakthrough papers including the study that found out that E-cigarettes can cause damage to the gum tissue. The study showed that e-cigarettes cause an increase in oxidative stress and cytokine release along with DNA damage. Flavored e-cigarettes increase the damage, and these processes cause gum tissue damage. There was a recent paper that found out that MET amplification could act as a therapeutic for gastric cancer. The study shows that prior screening with a PCR assay reduced the sample of people who would require FISH analysis for MET amplification.
Read more about Oncotarget on MSubmit
Search about Oncotarget on Pub Peer